Stock RTGN RETINALGENIX TECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials RetinalGenix Technologies Inc.

Equities

RTGN

US76133Y1055

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 12:47:02 2024-02-22 pm EST 		5-day change 1st Jan Change
3.5 USD +12.90% Intraday chart for RetinalGenix Technologies Inc. -.--% +13.27%
May. 20 RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 155.4 54.35
Enterprise Value (EV) 1 155.6 54.86
P/E ratio -35.8 x -25.6 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -82,865,939 x -26,042,527 x
EV / FCF -386,598,766 x -
FCF Yield -0% -
Price to Book -145 x -38.8 x
Nbr of stocks (in thousands) 17,272 17,589
Reference price 2 9.000 3.090
Announcement Date 3/31/23 4/1/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - - - - -1.876 -2.087
EBIT 1 -0.001464 -0.8058 -2.078 -2.177 -1.876 -2.087
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -0.001464 -0.8058 -2.078 -2.179 -3.914 -2.091
Net income 1 -0.001464 -0.8058 -2.078 -2.179 -3.914 -2.091
Net margin - - - - - -
EPS 2 -0.000054 -0.0229 -0.0523 -0.0528 -0.2511 -0.1205
Free Cash Flow - - -1.026 -0.7401 -0.4021 -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 2/16/21 2/16/21 8/5/21 4/15/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt - - - 0.07 0.16 0.51
Net Cash position - 0.05 0 - - -
Leverage (Debt/EBITDA) - - - - -0.0843 x -0.2427 x
Free Cash Flow - - -1.03 -0.74 -0.4 -
ROE (net income / shareholders' equity) - -6,678% 7,396% 800% 510% 169%
ROA (Net income/ Total Assets) - - -2,250% -4,121% -44,751% -579,736%
Assets 1 - - 0.0924 0.0529 0.008746 0.000361
Book Value Per Share 2 -0 0 -0 -0.0300 -0.0600 -0.0800
Cash Flow per Share - 0 0 0 0 -
Capex - - - - 0 -
Capex / Sales - - - - - -
Announcement Date 2/16/21 2/16/21 8/5/21 4/15/22 3/31/23 4/1/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
RETINALGENIX TECHNOLOGIES INC. Stock RetinalGenix Technologies Inc.
+13.27% 62.25M
MODERNA, INC. Stock Moderna, Inc.
+54.05% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RTGN Stock
  4. Financials RetinalGenix Technologies Inc.